Bacterial Pneumonia Market Rises on Tech Diagnostics & Japan's Aging Population | Innoviva Inc., Pfizer Inc., Merck & Co., Inc., Melinta Therapeutics LLC, Evopoint Biosciences

The global Bacterial Pneumonia market reached US$ 2.7 billion in 2022 and is expected to reach US$ 5.0 billion by 2030 growing with a CAGR of 8.1% during the forecast period 2024-2031.

Bacterial Pneumonia Market Report by DataM Intelligence offers a detailed assessment of the global respiratory and infectious-disease landscape, highlighting market size, key players, and critical growth drivers. With evolving stewardship programs, rapid pathogen diagnostics, and new severity-stratified care pathways, the report delivers strategic insights for stakeholders from 2025 to 2033.

In 2025, professional societies released updated guidance (notably a July 2025 ATS update addressing severe CAP) and hospitals increased adoption of rapid diagnostic algorithms to better target antibiotics both trends impacting diagnostics, antimicrobial stewardship tools, and acute-care therapeutics demand in the U.S. market.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/bacterial-pneumonia-market?ophp

Bacterial Pneumonia Market Competitors Overview:

Innoviva Inc., Pfizer Inc., Merck & Co., Inc., Melinta Therapeutics LLC, Evopoint Biosciences, Aridis Pharmaceuticals Inc., Cumberland Pharmaceuticals Inc., Eagle Pharmaceuticals, Inc., Clarametyx Biosciences and Basilea Pharmaceutica Ltd among others.

Important Industry Updates:

On July 27, 2023, Merck released encouraging topline findings from two Phase III studies assessing V116, the company's experimental 21-valent pneumococcal conjugate Drugs, in those who had never received a Drugs before and those who had. The first pneumococcal conjugate vaccination created especially for adults, if authorized, would be V116. Results from the STRIDE-3 trial showed that in adults who had never received a Drugs, serotype-specific opsonophagocytic activity (OPA) measured 30 days after vaccination revealed significant immune responses in comparison with PCV20 (pneumococcal 20-valent conjugate Drugs).

On June 1, 2023, the Phase III program, which included the ASSEMBLE (NCT03580044) and REVISIT (NCT03329092) studies evaluating the effectiveness, safety, and acceptability of the newly developed investigational antibiotic aztreonam-avibactam (ATM-AVI) combination in treating severe bacterial infections caused by Gram-negative bacteria, has produced encouraging results, according to Innoviva Inc. Data show that ATM-AVI is safe, efficacious, well-tolerated, and has an identical safety profile to that of aztreonam alone.

Methodology and Scope

The Bacterial Pneumonia Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/bacterial-pneumonia-market?ophp

Bacterial Pneumonia Market Segments Overview:

By Type {Community-Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP) (Ventilator-associated pneumonia (VAP), Healthcare-associated pneumonia (HCAP))} By Route of Administration (Oral, Subcutaneous, Others) By Treatments {Vaccines (Pneumococcal Conjugate Vaccines, Pneumococcal Polysaccharide Vaccine), Drugs (Fluoroquinolones, Monobactams, Tetracyclines, Macrolides, Carbapenems, Antibiotics)} By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Regional Overview for Bacterial Pneumonia Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=bacterial-pneumonia-market

The Report Covers:

âž¡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
âž¡ Strategic recommendations with a focused go-to-market approach.
âž¡ An unbiased evaluation of overall market performance.
âž¡ Region- and country-specific insights, with customized reports available upon request.
âž¡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the Bacterial Pneumonia market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Bacterial Pneumonia market?

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.